The Comptroller General of Drugs of India (DGCI) on Saturday approved the country’s first Covid-19 Clustered Regularly Interspaced Short Palindromic (CRISPR) test for commercial launch. This is developed by Tata and developed by CSIR-IGIB (Institute for Genomics and Integrative Biology) FELUDA (an acronym for FNCAS9 Editor-Limited Uniform Detection Assay).
“The approval of the Tata CRISPR test for COVID-19 will give a boost to the country’s efforts in the fight against the global pandemic. The commercialization of the Tata CRISPR test reflects the tremendous R&D talent in the country, which can collaborate to transform India’s contributions to the world of scientific research and global health, ”said Girish Krishnamurthy, CEO of TATA Medical and Diagnostics Ltd.
Read also | Covid-19 vaccine: Serum Institute will begin the final phase of the trial next week
What is the Tata CRISPR test?
* CRISPR is a genome editing technology for diagnosing diseases.
* The Tata CRISPR Covid-19 test uses state-of-the-art CRISPR technology developed in the country for the detection of the genomic sequence of the SARS-CoV-2 virus.
* This is the world’s first diagnostic test to implement a specially adapted Cas9 protein to successfully detect the virus that causes Covid-19.
* The Tata CRISPR test achieves the precision levels of traditional RT-PCR tests.
* However, it will take less time to process the results. The equipment is also less expensive.
.
